Impact of hyperprolactinemia in a patient with polyautoimmunity

Hyperprolactinemia has been proposed as a triggering factor for autoimmune diseases. The increased levels of prolactin could induce an abnormal immune response. Herein, we present a patient with hyperprolactinemia who developed polyautoimmunity. Patient's symptoms were associated with slightly...

Descripción completa

Detalles Bibliográficos
Autores principales: Rojas, Manuel, Rodríguez, Yhojan, Ramírez‐Santana, Carolina, Anaya, Juan‐Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333117/
https://www.ncbi.nlm.nih.gov/pubmed/30656000
http://dx.doi.org/10.1002/ccr3.1900
_version_ 1783387503521169408
author Rojas, Manuel
Rodríguez, Yhojan
Ramírez‐Santana, Carolina
Anaya, Juan‐Manuel
author_facet Rojas, Manuel
Rodríguez, Yhojan
Ramírez‐Santana, Carolina
Anaya, Juan‐Manuel
author_sort Rojas, Manuel
collection PubMed
description Hyperprolactinemia has been proposed as a triggering factor for autoimmune diseases. The increased levels of prolactin could induce an abnormal immune response. Herein, we present a patient with hyperprolactinemia who developed polyautoimmunity. Patient's symptoms were associated with slightly raised levels of prolactin (20‐40 ng/mL) and administration of dopaminergic agonists.
format Online
Article
Text
id pubmed-6333117
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-63331172019-01-17 Impact of hyperprolactinemia in a patient with polyautoimmunity Rojas, Manuel Rodríguez, Yhojan Ramírez‐Santana, Carolina Anaya, Juan‐Manuel Clin Case Rep Case Reports Hyperprolactinemia has been proposed as a triggering factor for autoimmune diseases. The increased levels of prolactin could induce an abnormal immune response. Herein, we present a patient with hyperprolactinemia who developed polyautoimmunity. Patient's symptoms were associated with slightly raised levels of prolactin (20‐40 ng/mL) and administration of dopaminergic agonists. John Wiley and Sons Inc. 2018-11-09 /pmc/articles/PMC6333117/ /pubmed/30656000 http://dx.doi.org/10.1002/ccr3.1900 Text en © 2018 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Rojas, Manuel
Rodríguez, Yhojan
Ramírez‐Santana, Carolina
Anaya, Juan‐Manuel
Impact of hyperprolactinemia in a patient with polyautoimmunity
title Impact of hyperprolactinemia in a patient with polyautoimmunity
title_full Impact of hyperprolactinemia in a patient with polyautoimmunity
title_fullStr Impact of hyperprolactinemia in a patient with polyautoimmunity
title_full_unstemmed Impact of hyperprolactinemia in a patient with polyautoimmunity
title_short Impact of hyperprolactinemia in a patient with polyautoimmunity
title_sort impact of hyperprolactinemia in a patient with polyautoimmunity
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333117/
https://www.ncbi.nlm.nih.gov/pubmed/30656000
http://dx.doi.org/10.1002/ccr3.1900
work_keys_str_mv AT rojasmanuel impactofhyperprolactinemiainapatientwithpolyautoimmunity
AT rodriguezyhojan impactofhyperprolactinemiainapatientwithpolyautoimmunity
AT ramirezsantanacarolina impactofhyperprolactinemiainapatientwithpolyautoimmunity
AT anayajuanmanuel impactofhyperprolactinemiainapatientwithpolyautoimmunity

Ejemplares similares